CA3238108A1 - Treatment of liver disorders with a thr-.beta. agonist - Google Patents

Treatment of liver disorders with a thr-.beta. agonist Download PDF

Info

Publication number
CA3238108A1
CA3238108A1 CA3238108A CA3238108A CA3238108A1 CA 3238108 A1 CA3238108 A1 CA 3238108A1 CA 3238108 A CA3238108 A CA 3238108A CA 3238108 A CA3238108 A CA 3238108A CA 3238108 A1 CA3238108 A1 CA 3238108A1
Authority
CA
Canada
Prior art keywords
compound
pharmaceutically acceptable
liver
dose
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3238108A
Other languages
English (en)
French (fr)
Inventor
Christopher T. Jones
Kevin Klucher
D. Barry CRITTENDEN
Erin K. QUIRK
Feng Jin
Matt Duan
Sheng Guo
Jianwei BIAN
Qianqian DONG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Terns Pharmaceuticals Inc
Original Assignee
Terns Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Terns Pharmaceuticals Inc filed Critical Terns Pharmaceuticals Inc
Publication of CA3238108A1 publication Critical patent/CA3238108A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
CA3238108A 2021-11-11 2022-11-11 Treatment of liver disorders with a thr-.beta. agonist Pending CA3238108A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2021130083 2021-11-11
CNPCT/CN2021/130083 2021-11-11
CNPCT/CN2022/097426 2022-06-07
CN2022097426 2022-06-07
PCT/CN2022/131297 WO2023083288A1 (en) 2021-11-11 2022-11-11 TREATMENT OF LIVER DISORDERS WITH A THR-β AGONIST

Publications (1)

Publication Number Publication Date
CA3238108A1 true CA3238108A1 (en) 2023-05-19

Family

ID=86335128

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3238108A Pending CA3238108A1 (en) 2021-11-11 2022-11-11 Treatment of liver disorders with a thr-.beta. agonist

Country Status (14)

Country Link
US (1) US20240293416A1 (cg-RX-API-DMAC7.html)
EP (1) EP4429666A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024544538A (cg-RX-API-DMAC7.html)
KR (1) KR20240101642A (cg-RX-API-DMAC7.html)
CN (1) CN118871113A (cg-RX-API-DMAC7.html)
AU (1) AU2022388507A1 (cg-RX-API-DMAC7.html)
CA (1) CA3238108A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024001399A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024007225A2 (cg-RX-API-DMAC7.html)
IL (1) IL312637A (cg-RX-API-DMAC7.html)
MX (1) MX2024005647A (cg-RX-API-DMAC7.html)
PE (1) PE20241327A1 (cg-RX-API-DMAC7.html)
TW (1) TW202332447A (cg-RX-API-DMAC7.html)
WO (1) WO2023083288A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121081472A (zh) 2018-12-13 2025-12-09 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
CA3154488A1 (en) 2019-08-23 2021-03-04 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
CA3154391A1 (en) 2019-09-12 2021-03-18 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
PE20252787A1 (es) 2023-04-07 2025-12-22 Terns Pharmaceuticals Inc Combinacion que comprende un agonista de thr-beta y un agonista de glp-1r para su uso en el tratamiento de un trastorno hepatico o una enfermedad cardiometabolica
WO2025245216A1 (en) * 2024-05-22 2025-11-27 Terns Pharmaceuticals, Inc. Treatment of liver disorders with a thr-beta agonist

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX394463B (es) * 2016-10-18 2025-03-19 Madrigal Pharmaceuticals Inc Métodos para tratar trastornos del hígado o trastornos lipídicos con un agonista de thr-beta.
TW202615431A (zh) * 2018-07-02 2026-04-16 美商瑪德瑞高製藥公司 2-(3,5-二氯-4-((5-異丙基-6-側氧基-1,6-二氫噠嗪-3-基)氧)苯基)-3,5-二側氧基-2,3,4,5-四氫-1,2,4-三嗪-6-腈之固體型式
CN121081472A (zh) * 2018-12-13 2025-12-09 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
WO2020228577A1 (zh) * 2019-05-10 2020-11-19 深圳微芯生物科技股份有限公司 一种哒嗪酮衍生物及其应用
WO2021121210A1 (zh) * 2019-12-16 2021-06-24 江苏恒瑞医药股份有限公司 并环类衍生物、其制备方法及其在医药上的应用
WO2021231646A1 (en) * 2020-05-13 2021-11-18 Terns Pharmaceuticals, Inc. Combination treatment of liver disorders
CN114437034A (zh) * 2020-11-06 2022-05-06 深圳微芯生物科技股份有限公司 一种酞嗪类化合物的可药用盐、晶型及其制备方法

Also Published As

Publication number Publication date
CL2024001399A1 (es) 2024-11-08
CN118871113A (zh) 2024-10-29
TW202332447A (zh) 2023-08-16
WO2023083288A1 (en) 2023-05-19
EP4429666A1 (en) 2024-09-18
PE20241327A1 (es) 2024-06-26
AU2022388507A1 (en) 2024-06-20
KR20240101642A (ko) 2024-07-02
JP2024544538A (ja) 2024-12-03
MX2024005647A (es) 2024-05-24
IL312637A (en) 2024-07-01
US20240293416A1 (en) 2024-09-05
EP4429666A4 (en) 2025-12-24
CO2024007225A2 (es) 2024-10-31

Similar Documents

Publication Publication Date Title
US20240293416A1 (en) TREATMENT OF LIVER DISORDERS WITH A THR-ß AGONIST
US20230241071A1 (en) Combination treatment of liver disorders
TWI667025B (zh) 治療肝臟疾病之方法
KR20210137467A (ko) 담즙 염 유출 펌프 결핍을 갖는 환자에서 asbti에 대한 유전자형 및 용량-의존성 반응
JP7053478B2 (ja) Fxrアゴニストを使用するための方法
TW202207928A (zh) 肝病之組合治療
AU2021273154A1 (en) Combination treatment of liver disorders
WO2023220404A1 (en) Treatment of non-alcoholic steatohepatitis
TW201900167A (zh) 治療肝疾病之方法
KR20240096642A (ko) 증가된 무사건 생존 (efs)을 위한 회장 담즙산 수송체 (ibat) 억제제를 사용한 치료제
EP3908279B1 (en) Lta4h inhibitor for the treatment or prevention of hidradenitis suppurativa
KR101057485B1 (ko) 1,2-디티올티온 유도체를 함유하는 엘엑스알-알파 과다발현으로 인한 질병의 예방 및 치료용 약학 조성물
TWI906348B (zh) 脂肪性肝疾病之治療劑
HK40118289A (en) TREATMENT OF LIVER DISORDERS WITH A THR-β AGONIST
CA3145824A1 (en) System for enhancing therapeutic compliance of the anti-cancer compound e7766
US20240165093A1 (en) Methods for treating familial chylomicronemia syndrome
US20130317034A1 (en) Combination therapy for treating diabetes
RU2857392C2 (ru) Способы лечения синдрома семейной хиломикронемии
RU2849641C1 (ru) Терапевтическое средство против жировой болезни печени
HK40113179A (en) Treatment with ileal bile acid transporter (ibat) inhibitors for increased event-free survival (efs)
TW202521110A (zh) 用於肝病之fasn抑制劑及glp-1促效劑之組合
HK40129994A (en) Genotype and dose-dependent response to an asbti in patients with bile salt export pump deficiency
CN118488832A (zh) 使用ssao抑制剂治疗肝脏病症

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241105

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241105

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241105

P22 Classification modified

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED

Effective date: 20241220

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251023

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251023